Illumina, Inc. $ILMN Shares Sold by Plato Investment Management Ltd

Plato Investment Management Ltd trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 41.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,228 shares of the life sciences company’s stock after selling 4,498 shares during the period. Plato Investment Management Ltd’s holdings in Illumina were worth $587,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC grew its position in Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares in the last quarter. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Illumina by 140.1% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after acquiring an additional 833,750 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock worth $69,528,000 after acquiring an additional 684,802 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Illumina in the third quarter valued at about $61,663,000. Finally, Invesco Ltd. raised its stake in shares of Illumina by 48.9% during the 2nd quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock worth $129,097,000 after purchasing an additional 444,543 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday. Barclays boosted their price objective on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. TD Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Finally, Guggenheim boosted their price target on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $130.00.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is owned by corporate insiders.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Illumina reported GAAP/non‑GAAP EPS of $1.35 (beat) and revenue of $1.16B (beat), with ex‑China growth stronger; management highlighted improving margins. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: FY‑2026 guidance mostly in line or better than Street — Illumina guided revenue to $4.5–$4.6B (above some estimates) and non‑GAAP EPS to $5.05–$5.20, signaling modest growth after recent year flatness. The guidance incorporates the SomaLogic acquisition and expected dilution. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: Underlying business trends cited as constructive — analysis points to clinical consumables growth, expansion into multiomics, and margin momentum that could support higher recurring revenue over time. ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum
• Neutral Sentiment: Call/transcript color: management reiterated strategy and provided details on growth drivers and the SomaLogic deal; read the call for guidance assumptions and segment commentary. Illumina Q4 2025 earnings call transcript Seeking Alpha transcript
• Negative Sentiment: Investors disappointed by FY‑2025 flat revenue and cautious tone — FY‑2025 revenue was essentially flat versus prior year, and some investors focused on slower organic growth and the near‑term dilution/costs from the SomaLogic acquisition, prompting selling pressure despite the EPS beat and guidance. Illumina shares tumble as flat revenue disappoints investors
• Negative Sentiment: Analyst/read‑through risk: even with some bullish commentary, markets may be repricing expectations for near‑term top‑line acceleration given mixed signals between margin upside and tepid full‑year growth. Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN)

Illumina Trading Down 10.4%

ILMN stock opened at $119.72 on Monday. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $138.43 and its 200-day moving average is $116.34. The firm has a market cap of $18.29 billion, a P/E ratio of 21.97, a P/E/G ratio of 1.98 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter last year, the company earned $0.95 EPS. Illumina’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.